The RAPS learning platform provider will be upgrading its security posture. This will take the system off-line from 20 July through the end of the day 23 July. This will affect any Online Course, eBook, and Virtual Program Attendance. Thank you for your patience.
Posted 01 March 2010 | By
The US Food and Drug Administration (FDA) announced the availability of Guidance for Industry: Contents of a Complete Submission for the Evaluation of Proprietary Names. This document will assist manufacturers in completing the submission, which is required for the review clock to begin. It will also help the agency evaluate the safety of proposed proprietary drug and biological product names by taking into account factors that can contribute to medication errors. In this guidance FDA discusses the information it requires from the manufacturers for the assessment of: